Table 1

Patient characteristics, RTX, comedications, rheumatoid arthritis and nodule assessment (Eular response: R (remission); MR (moderate response); NR (no response); NA (not available)).

PatientSexAgeNumber of TNF-blockers before RTXTreatment when nodules were discoveredPulmonary adverse event during TNF-blocker treatmentLast treatment before RTXComedications during RTXNumber of cycles before CT assessmentFollow-up until CT assessment (months)EULAR responseNumber of nodules before RTXNumber of nodules after RTXLong axis of nodules before RTX (mm)Long axis of nodules after RTX (mm)
Improvement1F633MTX+ETANewly discovered nodules (ETA)ETA+MTXMTX19R111913
2M512MTX+ETAPleurisy following nodule excavation (ETA)ETA+MTXMTX15MR111510
3F531MTXETANone212R118,77
4F791MTX+ADANewly discovered nodules (ADA)ADA+MTXNone17NR2111/79, 3/0
5F653MTXADA+MTXNone132NA2219/1116/9
6F701LEF+ETANewly discovered nodules (ETA)ETA+LEFLEF26MR3343/14/1240/8/8
7F591ETANewly discovered nodules (ETA) and pleurisy following nodule excavationSZPSZP+PQ325MR4433/9, 8/8, 8/6, 833/4/5, 9/3, 1
8F652MTXIncrease in number and size of pre-existing nodules (ETA)LEFMTX39R6023/20/16/15/12/110
Stable evolution9F613LEF+ADAADA+LEFMTX15MR11109, 5
Worsening10F591LEF+ETAETA+LEFLEF118MR5517/15/14/12/822/17/13/14/12
  • EULAR, European league against rheumatism; RTX, rituximab.